<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005119</url>
  </required_header>
  <id_info>
    <org_study_id>STHYS-JACOBS (completed)</org_study_id>
    <secondary_id>DK57869-01</secondary_id>
    <nct_id>NCT00005119</nct_id>
  </id_info>
  <brief_title>Altered Calcium and Vitamin D in PMDD or Severe PMS</brief_title>
  <official_title>Altered Calcium And Vitamin D Metabolism in PMDD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <brief_summary>
    <textblock>
      Osteoporosis has become one of the most widely recognized disorders of our times affecting an
      estimated 25 million women in this country. Recent evidence has suggested that premenstrual
      syndrome (PMS) is associated with a calcium deficiency state and bone loss. This may place
      premenopausal women at greater risk for osteoporosis. An entity such as PMS may be an
      important physiological marker of a calcium disturbance. The purpose of this investigation is
      to understand more completely the extent to which calcium balance is disturbed in severe PMS
      or Premenstrual Dysphoric Disorder (PMDD) by utilizing new tools to assess calcium and bone
      turnover. The long term objective is to elucidate the pathophysiology of PMDD or severe PMS
      as it relates to calcium hormones and bone markers. The experimental design involves the
      comparison between women witn severe PMS and asymptomatic controls.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2000</start_date>
  <completion_date>October 2003</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
  </study_design_info>
  <condition>Premenstrual Syndrome</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Measures of calcium and bone turnover</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Medical history of severe PMS for the PMS group

          -  No medical history of PMS for the control group

          -  Prospective 2 month documentation of moderate to severe symptoms for the PMS group

          -  Prospective 2 month documentation of absent symptoms for the control group

          -  General good health

          -  Regular menstrual cycles

          -  No history of metabolic bone disease

        Exclusion Criteria:

          -  Amenorrhea

          -  Anorexia nervosa

          -  Malabsorption

          -  Inflammatory bowel disease

          -  Erosive gastrointestinal disease

          -  Gastrectomy

          -  Malignancy

          -  Multiple myeloma

          -  Primary hyperparathyroidism

          -  Use of suppressive doses of thyroxine

          -  Cushing's syndrome

          -  Use of glucocorticoids or anticonvulsants

          -  Use of diuretics

          -  Metabolic bone disease

          -  Pregnancy or perimenopause or menopause

          -  Mental retardation

          -  Menstrual irregularity

          -  Significant gynecologic abnormality

          -  Use of birth control pills
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Thys-Jacobs, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St.Luke's-Roosevelt Hospital- Columbia Presbyterian Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Luke's-Roosevelt Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Thys-Jacobs, Silverton M, Alvir JM et al. Reduced Bone Mass in women with Premenstrual Syndrome. J Women's Health 1995; 4:161.</citation>
  </reference>
  <reference>
    <citation>Thys-Jacobs S, Ceccarelli S, Bierman A, Weisman H, Cohen MA, Alvir J. Calcium supplementation in premenstrual syndrome: a randomized crossover trial. J Gen Intern Med. 1989 May-Jun;4(3):183-9.</citation>
    <PMID>2656936</PMID>
  </reference>
  <reference>
    <citation>Thys-Jacobs S, Starkey P, Bernstein D, Tian J. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group. Am J Obstet Gynecol. 1998 Aug;179(2):444-52.</citation>
    <PMID>9731851</PMID>
  </reference>
  <reference>
    <citation>Thys-Jacobs S, Alvir MJ. Calcium-regulating hormones across the menstrual cycle: evidence of a secondary hyperparathyroidism in women with PMS. J Clin Endocrinol Metab. 1995 Jul;80(7):2227-32.</citation>
    <PMID>7608284</PMID>
  </reference>
  <reference>
    <citation>Lee SJ, Kanis JA. An association between osteoporosis and premenstrual symptoms and postmenopausal symptoms. Bone Miner. 1994 Feb;24(2):127-34.</citation>
    <PMID>8199532</PMID>
  </reference>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2000</study_first_submitted>
  <study_first_submitted_qc>April 19, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2000</study_first_posted>
  <last_update_submitted>March 1, 2010</last_update_submitted>
  <last_update_submitted_qc>March 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 2, 2010</last_update_posted>
  <keyword>Premenstrual Dysphoric Disorder</keyword>
  <keyword>Severe Premenstrual Syndrome</keyword>
  <keyword>Calcium metabolism</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Bone Markers</keyword>
  <keyword>Premenopausal</keyword>
  <keyword>Menstrual Cycle</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premenstrual Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

